Yale School of Medicine, Yale New Haven Hospital, New Haven, CT, USA.
Phlebology. 2020 Sep;35(8):556-560. doi: 10.1177/0268355520905178. Epub 2020 Feb 6.
Compression therapy is the mainstay of treatment for patients with venous ulcer disease. There exists a lack of certainty as to the safety of compression therapy in patients with congestive heart failure.
A retrospective review of 95 patients with the diagnosis of congestive heart failure (systolic, diastolic, or combined), who underwent compression therapy at the wound care center of a large teaching hospital between January 2013 and June 2019, was performed. Patient outcomes including mortality, weight gain, admission for heart failure decompensation, and requirement for diuretic dose increase were compared to the general congestive heart failure population as well as to the registry data.
In the compression cohort, with a mean compression period of 310 days, seven patients (7.3%) were admitted for congestive heart failure exacerbation and six (6.3%) underwent diuretic dosage increase. Two patients (2.1%) died during the compression period. These endpoints were not significantly higher than within the general congestive heart failure population.
Compression therapy appears safe amongst patients with stable congestive heart failure.
压迫疗法是治疗静脉溃疡病患者的主要方法。对于充血性心力衰竭患者,压迫疗法的安全性尚不确定。
回顾性分析了 2013 年 1 月至 2019 年 6 月期间在一家大型教学医院的伤口护理中心接受压迫疗法的 95 例充血性心力衰竭(收缩性、舒张性或混合性)患者的病历。将患者的预后(死亡率、体重增加、心力衰竭失代偿入院和利尿剂剂量增加的需求)与一般充血性心力衰竭人群以及登记数据进行比较。
在压迫治疗组中,平均压迫治疗期为 310 天,有 7 例(7.3%)因充血性心力衰竭恶化入院,6 例(6.3%)需要增加利尿剂剂量。在压迫治疗期间有 2 例(2.1%)患者死亡。这些终点与一般充血性心力衰竭人群相比没有显著更高。
对于稳定的充血性心力衰竭患者,压迫疗法似乎是安全的。